Dennis Thomas, Vanessa M McDonald, Sean Stevens, Erin S Harvey, Melissa Baraket, Philip Bardin, Jeffrey J Bowden, Simon Bowler, Jimmy Chien, Li Ping Chung, Andrew Gillman, Mark Hew, Sandra Hodge, Alan James, Christine Jenkins, Constance H Katelaris, Gregory P Katsoulotos, David Langton, Joy Lee, Guy Marks, Matthew Peters, Naghmeh Radhakrishna, Paul N Reynolds, Janet Rimmer, Pathmanathan Sivakumaran, John W Upham, Peter Wark, Ian A Yang, Peter G Gibson
BACKGROUND: Asthma remission has emerged as a potential treatment goal. This study evaluated the effectiveness of two biologics (mepolizumab/omalizumab) in achieving asthma remission. METHODS: This observational study included 453 severe asthma patients (41% male; mean age ± SD 55.7 ± 14.7 years) from two real-world drug registries: the Australian Mepolizumab Registry and the Australian Xolair Registry. The composite outcome clinical remission was defined as zero exacerbations and zero oral corticosteroids during the previous 6 months assessed at 12 months and 5-item Asthma Control Questionnaire (ACQ-5) ≤1 at 12 months...
August 25, 2023: Allergy